Skip to main content
BBC logo
BBC
(NYSEARCA)
Virtus LifeSci Biotech Clinical Trials ETF
$42.84-- (--)
Loading... - Market loading

BBC ETF: Virtus LifeSci Biotech Clinical Trials ETF - Price, Holdings & Analysis

Virtus LifeSci Biotech Clinical Trials ETF Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$40.89 - $43.09
52-Week High$44.10
52-Week Low$13.42
Open$41.15
Volume11.97K
Average Volume (3M)11.97K
Assets (AUM)38.68M
Expense Ratio0.79%
Total Holdings125
Inception DateDec 15, 2014
1 Day Change1.91%
1 Month Change0.45%
6 Month Change52.67%
YTD Change12.73%
1 Year Change145.91%
52-Week Change156.62%
5 Year Change-17.82%
10 Year Change116.95%
50-Day MA$41.34
200-Day MA$31.84
RSI56.10
Stochastic %K89.60
Stochastic %D59.06
Annual Dividend$0.66
Dividend Yield1.54%
Last Dividend Ex-DateDec 29, 2026
Dividend Growth YoY172.92%
Years Dividend Growth2

Frequently Asked Questions About Virtus LifeSci Biotech Clinical Trials ETF

What is the current price of BBC?

The latest BBC price is $42.84. The 52-week range is $13.42–$44.10. BBC has returned 156.6% over the past 52 weeks.

What is the expense ratio for BBC?

BBC's annual expense ratio is 0.79%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equitys in the ETF Screener.

Does BBC pay dividends?

Yes, BBC pays a 1.54% dividend yield. The last ex-dividend date was 2026-12-29. View full dividend history in the Dividends section.

What are the top holdings of BBC?

BBC's largest holdings are Erasca, Inc. (3.5%), Tango Therapeutics, Inc. (1.7%), Enliven Therapeutics, Inc. (1.7%) (combined weight: 6.9%). The fund holds 125 total positions. View the complete portfolio breakdown in the Holdings section.

How does BBC compare to similar ETFs?

Compare BBC (0.79% expense ratio, $39M AUM) against similar Equitys using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.